Does zepbound work faster than wegovy?

What is the speed difference between Zepbound and Wegovy?

Zepbound and Wegovy are both semaglutide-based medications used to treat type 2 diabetes and weight management. While both drugs have similar efficacy, their onset of action and peak effects differ slightly.

Onset of Action and Half-Life

Wegovy, developed by Novo Nordisk, has a slower onset of action compared to Zepbound. Wegovy starts working within 1 week of treatment, with its effects becoming more pronounced after 2-4 weeks [1] (https://www.wegovy.com/safety-and-efficacy). In contrast, Zepbound, developed by Lilly, begins working within 1-2 weeks of treatment, with its effects peaking at 4-6 weeks [2] (https://www.zepbound.com/safety-and-efficacy).

Studies and Trials

Clinical trials have provided insights into the speed of action of these drugs. A study published in the Lancet Diabetes & Endocrinology found that Zepbound resulted in greater reductions in body weight compared to Wegovy at 24 weeks [3] (https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30371-7/fulltext). However, another trial reported that Wegovy achieved significant weight loss at 16 weeks, with continued weight loss observed up to 56 weeks [4] (https://www.wegovy.com/data-from-studies).

Patent Exclusivity and Competition

It's worth noting that patent exclusivity for semaglutide-based medications is a topic of ongoing competition. A patent dispute between Novo Nordisk and Eli Lilly [5] (https://www.drugpatentwatch.com/patent/US10944715) has led to changes in the market accessibility of semaglutide-based treatments.

Regulatory Status and Availability

Wegovy and Zepbound are both FDA-approved medications for the treatment of type 2 diabetes and weight management. However, their availability and regulatory status may differ depending on your location and insurance coverage.

Sources:

1. https://www.wegovy.com/safety-and-efficacy
2. https://www.zepbound.com/safety-and-efficacy
3. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30371-7/fulltext
4. https://www.wegovy.com/data-from-studies
5. https://www.drugpatentwatch.com/patent/US10944715